Pfizer weighs 'strategic options' for newly FDA-approved Remicade biosim, its second
admin 14th December 2017 Uncategorised 0Pfizer, already laboring to pick up market share with its Remicade biosimilar Inflectra, now has a second FDA-approved copycat. Don’t expect a sales boost from Ixifi, though. Pfizer has no plans to launch it.
More: Pfizer weighs 'strategic options' for newly FDA-approved Remicade biosim, its second
Source: fierce